Vertex ousts COO Ian Smith over ‘personal behaviour’
Boston-based firm Vertex Pharmaceuticals has fired Chief Operating Officer (COO) and interim Chief Financial Officer (CFO) Ian Smith. Smith’s termination, which is said to be unrelated to the company’s financial and business performance is effective immediately.
The company cited Smith’s “personal behaviour” which it claimed “violated Vertex’s Code of Conduct and values”.
Dr Jeffrey Leiden, Chairman, President and Chief Executive Officer of Vertex, commented: “At Vertex, we are deeply committed to our culture of diversity, inclusion and respect, and we insist that all of our employees, regardless of their seniority, live our values and adhere to our Code of Conduct. This decision was not related to any conduct concerning the company’s operations or finances.”
“Vertex has a strong management team in place, as well as a deep bench. In 2019 and beyond, I am confident that we will continue to successfully execute the company’s long-standing strategy to bring transformative treatments to all people living with cystic fibrosis (CF) and advance our diverse pipeline of medicines for other serious diseases,” Leiden added.
“Making a difference in the lives of patients, their families and their caregivers is our true north, and our commitment to this ideal is unwavering.”
Vertex has revealed that it has secured a new approval from the European Commission for …
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has given …
Data revealed on novel CRISPR/Cas9 gene-editing therapy for first two severe haemoglobinopathy patients
Vertex and CRISPR Therapeutics have unveiled the first interim Phase 1/2 data demonstrating the safety …